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Cisplatin  is a chemotherapeutic  agent  used  in  the  treatment  of  solid  tumors,  with clinical  use  often
complicated  by kidney  toxicity.  Nuclear  factor  (erythroid-derived-2)-like  2  (Nrf2)  is  a  transcription  factor
involved  in  kidney  protectant  effects.  The  purpose  of  this  study  was  to  determine  whether  the  Nrf2
activators  oltipraz,  sulforaphane,  and  oleanolic  acid  could  protect  human  kidney  cells against  cisplatin-
induced  injury  and  to compare  the protective  effects  between  three  Nrf2  activators.  Human  proximal






in  the  absence  and  presence  of Nrf2  activators.  Pre- and  delayed-cisplatin  and  Nrf2  activator  exposures
were  also assessed.  Cell  viability  was  enhanced  with  Nrf2 activator  exposures,  with  differences  detected
between  pre-  and  delayed-treatments.  Both  sulforaphane  and  oltipraz  increased  the  expression  of anti-
oxidant  genes  GCLC  and  NQO1.  These  ﬁndings  suggest  potential  human  kidney  protective  beneﬁts  of Nrf2
activators  with  planned  exposures  to cisplatin.
©  2016  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
leanolic acid
. Introduction
Cisplatin (cis-diamminedichloroplatinum) is one of the most
ommonly used chemotherapy drugs for the treatment of solid
umors. Cisplatin and other related platinum-based therapeutics
re effective against lung, head and neck, prostate, ovarian, and
ladder cancers [1–3]. However, acute kidney injury can develop
fter a single dose. Existing clinical studies report reductions in
stimated glomerular ﬁltration rates, increases in urinary albumin
xcretion, and elevations in serum creatinine within 10 days fol-
owing a cisplatin dose in 8–40% of patients [4–7]. Kidney disease
anifestations can also include electrolyte wasting and persistent
ypomagnesemia [8]. Nephrotoxicity may  limit cisplatin’s clinical
se and resultant treatment efﬁcacy. Current therapies, including
uid administration have variable efﬁcacy in preventing kidney
amage. Thus, interventions that can prevent or ameliorate kidney
njury in human kidney cells exposed to cisplatin are warranted.
∗ Corresponding author at: The University of Colorado, Skaggs School of Pharmacy
nd Pharmaceutical Sciences, Department of Pharmaceutical Sciences, Mail Stop
238, Room V20-4108, 12850 E. Montview Blvd, Aurora, CO 80045, United States.
E-mail address: Melanie.Joy@ucdenver.edu (M.S. Joy).
ttp://dx.doi.org/10.1016/j.toxrep.2016.01.006
214-7500/© 2016 Published by Elsevier Ireland Ltd. This is an open access article under license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Several mechanisms contribute to the onset and pathogene-
sis of cisplatin-induced kidney injury, including vascular injury,
inﬂammation, ischemia, oxidative stress, and tubular cell death
[3,6,9–11]. Although cisplatin nephrotoxicity involves many dif-
ferent mechanisms, tubular cell death plays an important role
in its progression. Studies using cultured renal tubular cells
exposed to cisplatin demonstrated apoptotic and necrotic cell
death [12]. These results were conﬁrmed in animals, where both
necrosis and apoptosis were induced in renal tubules following cis-
platin administration [13–15]. Another study found that cisplatin
administration in rats increases oxidative stress resulting in down-
regulation of tight junction proteins and potentiation of proximal
tubule damage [16]. Reducing exposure of tubule cells to cisplatin
is an approach to limit kidney toxicity.
Prior research demonstrated enhanced kidney injury in
Nrf2-null mice [17,18] suggesting a protective effect from this tran-
scription factor. Under non-stressed conditions, Nrf2 is sequestered
in the cytosol by kelch-like ECH associating protein 1 (Keap1)
[19]. However, when oxidative stress, electrophilic stress, or the
presence of Nrf2 activators becomes prevalent, Nrf2 and Keap1 dis-
sociate resulting in accumulation of free Nrf2 in the cytosol and an
increase in Nrf2 translocation into the nucleus [20]. Once in the
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ucleus, Nrf2 heterodimerizes and binds to antioxidant response
lements (ARE) which leads to the transcription of various cyto-
rotective and antioxidant genes [21]. Activation of transcription
actors such as Nrf2 that regulate uptake and efﬂux transporters
ocalized to kidney proximal tubule is a strategy to modulate cis-
latin exposures [6,17]. As Nrf2 can regulate proteins involved in
he metabolism and excretion of organic chemicals [22], treatment
ith Nrf2 activating compounds, including oltipraz, sulforaphane,
nd oleanolic acid, would be a plausible approach to limit expo-
ure of human kidney cells to cisplatin. For the current study, we
imed to explore the therapeutic potential of known Nrf2 activators
o modulate cisplatin-induced human kidney cell injury. Further-
ore, we sought to determine optimal exposure regimens for Nrf2
ctivating compounds for nephrotoxicity prophylaxis and favor-
ble effects on Nrf2 antioxidant genes with exposure to cisplatin.
. Materials and methods
.1. Cell culture & reagents
Human embryonic kidney 293 (HEK293, ATCC, Rockville, MD)
nd human proximal tubule epithelial (hPTC, ScienCell, Carlsbad,
A) cells were used for in vitro studies. HEK293 cells were routinely
rown and maintained in Dulbecco’s modiﬁed Eagle’s medium
DMEM) supplemented with 10% fetal bovine serum (FBS), 1% Peni-
illin/Streptomycin per product information (Life Technologies,
rand Island, NY). Epithelial cell medium (EpiCM, ScienCell) sup-
lemented with 2% fetal bovine serum, 1% epithelial cell growth
upplement, and 1% Penicillin/Streptomycin was used to culture
PTC cells. Cells were maintained at 37 ◦C in a humidiﬁed incu-
ator with an atmosphere of 5% CO2. Cisplatin (Sigma Chemical
o., St. Louis, MO)  was dissolved in dimethyl sulfoxide (DMSO)
Sigma Chemical Co.) to 100 mM.  Nrf2 activators (sulforaphane,
ltipraz, and oleanolic acid) were purchased (Sigma Chemical Co.)
nd dissolved in DMSO. Cells were treated with Nrf2 activators
ither before or after cisplatin exposure. Unless speciﬁed otherwise,
he doses of Nrf2 activators (sulforaphane, oltipraz, and oleanolic
cid) were 5, 12, and 5 M,  respectively. RNA extraction kits were
urchased from Life Technologies. PCR reagents and Taqman gene
xpression assays were obtained from Life Technologies.
.2. Cell viability assay
HEK293 and hPTCs were plated in a 96-well conﬁguration. Cells
ere incubated overnight at 37 ◦C in a humidiﬁed incubator with
n atmosphere of 5% CO2 prior to treatment. The cell treatments
onsisted of 1) 0.1% vehicle control (DMSO), 2) cisplatin at 0, 50,
0 M doses (LC50 23.4–60 M),  3) Nrf2 activator [sulforaphane
5 M),  oleanolic acid (5 M),  or oltipraz (12 M)], or 4) cisplatin
at the above doses) combined with a Nrf2 activator at speciﬁed
oses. Cells were incubated with Nrf2 activators for 12, 24, or 48 h
eginning either 3 h prior to cisplatin or 3 h after initiation of cis-
latin exposure. After the speciﬁed incubation time, MTT  reagent
2 mg/mL) (Sigma Aldrich) in DMEM or EpiCM containing no FBS
as added and cells were incubated for 4 h at 37 ◦C. MTT  reagent
as removed after the 4 h incubation period, MTT  solubility solu-
ion (2% HCl, 25% H2O, 73% 2-propanol) was added and cell viability
as analyzed at 550 nm by VersaMax microreader plate (Molecular
evices, Sunnyvale, CA).
.3. Gene expressionGene expression was only evaluated in hPTCs to enable a closer
n vitro approximation to humans. The expression of NFE2L2/NRF2
nd detoxifying enzymes GCLC and NQO1 were evaluated in hPTCs Reports 3 (2016) 153–159
that received Nrf2 activators before and after treatment with cis-
platin. For these studies cisplatin doses of low, moderate, and high
were chosen. The cell treatments consisted of 1) 0.1% vehicle con-
trol (DMSO), 2) cisplatin at 0, 5, 25 and 80 M doses, 3) Nrf2
activator [sulforaphane (5 M),  oleanolic acid (5 M),  or oltipraz
(12 M)], or 4) cisplatin (5, 25, 80 M)  combined with a Nrf2 activa-
tor at the speciﬁed doses. Cells were harvested for gene expression
studies at 12, 24, or 48 h post treatment. Cells were collected and
lysed and total mRNA prepared from cell lysates using Ambion RNA
Extraction Kit (Life Technologies). cDNA was generated using Taq-
man  reverse transcription reagents (Applied Biosystems) and an
Applied Biosystems 2720 thermal cycler. Commercial gene expres-
sion assays: GCLC (Hs00155249), NQO1 (Hs02512143), NFE2L2
(Hs00975961), and housekeeping gene GAPDH (Hs02758991) were
used (Applied Biosystems). Real-time PCR was performed using
the 7500 Real Time PCR system. Generated data was  analyzed by
relative quantitation using the comparative CT method (2−CT).
2.4. Statistical analysis
The data were expressed as mean ± SEM. Graphs were cre-
ated using Graph Pad Prism 4.0 (GraphPad Software, Inc., San
Diego, CA). Analysis was  performed using GraphPad InStat 3.0.
Data were analyzed using the one-way analysis of variance with
Student–Newman–Keuls post hoc test for groups of 3 or more. Dif-
ferences were considered statistically signiﬁcant at p < 0.05.
3. Results
3.1. Cisplatin toxicity: exposure of hPTC and HEK293 cells to
cisplatin
We  analyzed the viability of hPTCs and HEK293 cells following
exposure to cisplatin (50 and 80 M)  for 12, 24, or 48 h. Cisplatin
doses of 50 M and above resulted in signiﬁcantly lower hPTC
and HEK293 cell viability. hPTCs and HEK293 cells treated with
cisplatin alone demonstrated decreased survival over time, with
hPTCs demonstrating more sensitivity to cisplatin (Fig. 1A & B).
After 12, 24, and 48 h incubation with cisplatin, only 59%, 57% and
5% of hPTCs treated with 50 M cisplatin were viable compared
to vehicle controls, respectively (Fig. 1A). HEK293 cells incubated
with cisplatin (50 M)  exhibited 75% viability during the ﬁrst 12 h
of exposure (Fig. 1B). After 24 and 48 h incubation with cisplatin
(50 M),  cell viability was  57% and 18%, respectively (Fig. 1B). Cell
viability was further decreased in hPTCs and HEK293 cells treated
with 80 M cisplatin (Fig. 1A & B).
3.2. Cisplatin toxicity: pre- and delayed-treatment with NRF2
activators
hPTCs cells were treated before (pre-treatment) or after
(delayed treatment) cisplatin (50 and 80 M) with Nrf2 activa-
tors for 12, 24, and 48 h, respectively. Preliminary cell viability
experiments determined the optimal Nrf2 activator doses for sul-
foraphane, oleanolic acid, and oltipraz to be 5 M,  5 M,  and 12 M,
respectively. hPTCs treated with 80 M cisplatin had decreased cell
viability compared to vehicle controls (Fig. 2A). hPTCs pre-treated
with oltipraz or oleanolic acid had greater cell viability rela-
tive to cisplatin 80 M alone treated cells (Fig. 2A). Sulforaphane
demonstrated less impressive results than oltipraz and oleanolic
acid when compared to cisplatin 80 M alone and vehicle control
treated cells. However, pre-treatment with sulforaphane displayed
greater viability at 24 h and 48 h relative to cisplatin alone treated
cells. Delayed-treatment with oltipraz and oleanolic acid at 12
and 24 h demonstrated higher cell viability as compared to cis-
platin 80 M alone treated cells (Fig. 2B). Delayed-treatment with
A. Atilano-Roque et al. / Toxicology Reports 3 (2016) 153–159 155
Fig. 1. Cell viability of hPTCs and HEK293 cells after exposure to 50 or 80 M cis-































Fig. 2. Survival of hPTCs treated pre- or delayed-cisplatin (50 or 80 M)  with Nrf2
activators [oltipraz (12 M),  sulforaphane (5 M),  oleanolic acid (5 M)]  incubated
for  12, 24, or 48 h. (A) hPTCs treated pre- cisplatin (80 M) with Nrf2 activators,
(B)  hPTC treated with delayed- cisplatin (80 M)  with Nrf2 activators, (C) hPTCs
treated pre- cisplatin (50 M) with Nrf2 activators, and (D) hPTCs treated with
delayed- cisplatin (50 M)  with Nrf2 activators. Data are means ± SEM. (n = 4–6).
*p < 0.05 compared to vehicle controls (DMSO), #p < 0.05 compared to 50 M orompared to vehicle control (DMSO). (B). HEK293 viability after 12, 24 h or 48 h
ncubation with 50 or 80 M cisplatin compared to vehicle control (DMSO). Data
re means ± SEM. (n = 4-6). *p < 0.05 compared to vehicle control (DMSO).
ulforaphane failed to demonstrate improved cell viability over cis-
latin 80 M alone treated cells. hPTCs treated with 50 M cisplatin
nd pre-treatment with Nrf2 activators resulted in comparable cell
iability to results observed at 80 M (Fig. 2C). Delayed-treatment
ith oltipraz resulted in signiﬁcantly enhanced cell viability com-
ared to control and cisplatin 50 M alone at 12 h (Fig. 2D).
HEK293 cells were also treated before (pre-treatment) or after
delayed treatment) cisplatin (80 M)  with Nrf2 activators for 12,
4, and 48 h. HEK293 cells treated pre- and delayed-cisplatin 80 M
ith Nrf2 activators at 12 h resulted in enhanced cell viability in
omparison to cisplatin alone (Fig. 3A). Delayed-treatment with
ulforaphane at 24 h resulted in statistically signiﬁcantly higher
ell viability compared to vehicle controls and cisplatin 80 M
lone treatment (Fig. 3B). Delayed-treatment with oltipraz at 24 h
esulted in higher cell viability compared to cisplatin treatment
Fig. 3B). Pre-treatment with the Nrf2 activators at 24 h and 48 h
nd delayed-treatment at 48 h resulted in HEK293 cell viability
hat was less than vehicle controls and cisplatin alone treatments.
re-treatment with Nrf2 activators resulted in enhanced cell viabil-
ty compared to cisplatin 50 M alone treatments at 48 h (Fig. 3C).
EK293 cells treated with 50 M cisplatin and delayed treatment
ith Nrf2 activators displayed comparable cell viability to results
bserved at 80 M (Fig. 3D).
.3. Expression of Nrf2, GCLC, and NQO1 in hPTCs
.3.1. Cisplatin alone
The mRNA expression of antioxidant genes was evaluated in
PTCs exposed to cisplatin (5, 25, and 80 M).  Cisplatin doses were
hosen to represent low, moderate, and high exposures in humans.
reatment with 5 M and 25 M cisplatin resulted in increased80  M cisplatin-treated cells.
mRNA expression of NFE2L2 at 12 h compared to vehicle controls
(Fig. 4A). There was no observable expression with 80 M cisplatin
dose. Cisplatin treatment at 24 h (5 M)  incubation and at 48 h incu-
bation (5 M and 25 M)  resulted in increased mRNA expression
of the Nrf2 target gene GCLC over vehicle control (Fig. 4B). Cisplatin
treatment with 5 and 25 M resulted in increased mRNA expres-
sion of NQO1 at 24 h compared to vehicle controls (Fig. 4C). There
was no observable expression at 12 h and 48 h incubation. Treat-
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Fig. 3. Survival of HEK293 cells treated pre- or delayed-cisplatin (50 or 80 M)
with Nrf2 activators [oltipraz (12 M),  sulforaphane (5 M),  oleanolic acid (5 M)]
incubated for 12, 24, or 48 h. (A) HEK293 cells treated pre- cisplatin (80 M)  with
Nrf2  activators, (B) HEK293 cells treated with delayed-cisplatin (80 M) with Nrf2








Fig. 4. mRNA expression of antioxidant genes NFE2L2, GCLC, and NQO1 in hPTCs.
Total mRNA was  isolated from hPTCs following treatment with cisplatin 5 M,D)  HEK293 cells treated with delayed-cisplatin (50 M)  with Nrf2 activators. Data
re means ± SEM. (n = 4–6). *p < 0.05 compared to vehicle controls (DMSO), #p < 0.05
ompared to 50 M or 80 M cisplatin-treated cells.
ent with 80 M cisplatin displayed gene expression that was
imilar to vehicle control conditions..4. Nrf2 activators alone
Sulforaphane alone resulted in a 4-fold increase in mRNA
xpression of NFE2L2 compared to vehicle controls at 24 h (Fig. 525 M,  or 80 M after 12, 24, and/or 48 h and probed for (A) NFE2L2, (B) GCLC, and
(C)  NQO1. Gene expression was analyzed by RT-PCR. GAPDH was  used as endogenous
control. Data are means ± SEM. (n = 3) *p < 0.05 compared to vehicle control (DMSO).
A). Neither oltipraz nor oleanolic acid led to an increase in NFE2L2
mRNA expression. Treatment with sulforaphane alone resulted in
an up-regulation of GCLC expression 4.5-fold, at 48 h compared to
vehicle controls (Fig. 5B).
3.5. Pre- and delayed-treatment with Nrf2 activators
Pre- and delayed-cisplatin treatment with oleanolic acid had no
effect on mRNA expression of NFE2L2 or detoxifying genes (GCLC
and NQO1)  (data not shown). Pre- and delayed-cisplatin treat-
ment with sulforaphane resulted in an enhancement of GCLC mRNA
expression compared to vehicle controls at 48 h (Fig. 5B). How-
ever, the transcription effects were greater when sulforaphane was
administered prior to cisplatin. Pre-treatment with sulforaphane
and oltipraz resulted in increased NQO1 mRNA expression at
24 h compared to vehicle controls (Fig. 5C). Changes to NQO1
mRNA expression were not observed with sulforaphane or oltipraz
A. Atilano-Roque et al. / Toxicology
Fig. 5. mRNA expression of antioxidant genes NFE2L2, GCLC, and NQO1 in
hPTCs exposed to Nrf2 activators. (A) NFE2L2 mRNA expression was assessed
at  24 h after administration of Nrf2 activators. (B) GCLC mRNA expression
was  assessed at 48 h after administration of Nrf2 activators and pre- or
delayed-cisplatin administration. (C) NQO1 mRNA expression was  assessed
at  24 h after administration of Nrf2 activators and pre- or delayed-cisplatin
administration. Doses of Nrf2 activators were: sulforaphane (5 M), oltipraz Reports 3 (2016) 153–159 157
treatment alone. Pre- and delayed-cisplatin treatment with Nrf2
activators did not enhance mRNA expression of NFE2L2.
4. Discussion
The present study investigated the feasibility of three known
Nrf2 activators to mitigate cisplatin toxicity in human kidney cells.
HEK293 cells were selected for this study as an immortalized in
vitro kidney model. hPTCs were selected for this study to enable
a close in vitro approximation to humans. hPTC were used in
all gene expressions studies due to the lack of previously pub-
lished data in primary cells and due to their higher sensitivity
to drug-induced toxicity. Exposure to Nrf2 activators produced
favorable patterns of viability in both hPTCs and HEK293 cells.
hPTCs pre-treated with Nrf2 activators exhibited favorable cell via-
bility compared to cisplatin-only treated cells, with oltipraz and
oleanolic acid demonstrating the most favorable cell viability pro-
ﬁle. HEK293 cells displayed higher cell viability when treated with
pre- and delayed-Nrf2 activators versus cisplatin alone treatment,
with all three Nrf2 activators performing similarly. Previous stud-
ies demonstrated, in vitro, that pre-treatment with sulforaphane,
oleanolic acid, and oltipraz results in higher cell viability upon
exposure to cisplatin and other toxicants [23–25]. The previously
published data, in addition to our current ﬁndings in hPTCs, support
cell viability protection of Nrf2 activators with anticipated cisplatin
exposures. These data suggest that Nrf2 activators may  be promis-
ing therapeutics to limit tubular apoptosis and necrosis during AKI
and to stimulate subsequent regeneration.
In contrast to previous studies, we investigated a comparison
between three known Nrf2 activators. In addition to Nrf2 activators,
several studies have evaluated other compounds as potential mod-
ulators of cisplatin-induced toxicity and oxidative stress [26–28].
For example, pre-stimulation of the kallikrein system with a high
potassium diet was  found to reduce tissue markers of oxidative
stress in a model of nephrotoxicity induced by cisplatin [26].
A novel assessment in the current study is the ﬁnding of differ-
ential effects of the three investigated Nrf2 activators on expression
of antioxidant defense genes in human kidney cells and evaluation
of pre-versus delayed-exposure regimens. Sulforaphane exhibited
the greatest induction of GCLC and NQO1 when administered con-
comitantly with cisplatin, with the collective results demonstrating
greatest antioxidant effects when sulforaphane was administered
prior to cisplatin exposure. Since sulforaphane alone resulted
in an increase in NFE2L2 mRNA expression, induction of Nrf2
inducible genes such as GCLC prior to cisplatin would contribute
to a primed anti-oxidant environment and protect cells against
oxidative damage allowing survival and regenerative responses The
renoprotective effect of sulforaphane was  mediated, at least in part,
by activation of the GCLC detoxifying gene.
Oleanolic acid alone resulted in a modest increase in NFE2L2
mRNA expression. These ﬁndings are in contrast to previous studies
conducted in acetaminophen hepatoxicity models where oleano-
lic acid increased mRNA expression by 4-fold in livers of wild-type
mice [29]. It is important to note that the concentrations of oltipraz
and oleanolic acid were lower in our study using human kidney
cells versus data previously reported in RAW 264.7 and PC12 cells
[24,25], and may  contribute to our ﬁndings Moreover, previous
studies suggest oleanolic acid is unable to activate the Nrf2 pathway
due to the lack of functional groups including Michael acceptors
[30,31], as well as an inability to induce Nqo1 activity at low doses
in vitro in hepa1c1c7 murine hepatoma cells [30]. Doses of Nrf2
(12 M),  and oleanolic acid (5 M).  S = sulforaphane and O = oltipraz. Gene expres-
sion was  analyzed by RT-PCR. GAPDH was used as endogenous control. Data are
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ctivators used in our study were selected based on preliminary
ell viability experiments that determined optimal Nrf2 activator
oses for sulforaphane, oleanolic acid, and oltipraz.
We examined NFE2L2 expression in hPTCs pre- or delayed-
isplatin with Nrf2 activators, but did not observe any induction.
 previous report suggested that mice treated with Nrf2 activators
ncluding oltipraz and sulforaphane have enhanced Nrf2-mediated
ranscription in the liver but not in the kidneys [17], suggesting
 differential tissue-speciﬁc Nrf2 activation response. It is cur-
ently unknown whether this response is due to differences in
issue disposition related to Nrf2 activator pharmacokinetics [17].
uture studies will be designed to understand how sulforaphane,
ltipraz, and oleanolic acid activate Nrf2 in the kidneys. In addi-
ion to Nrf2-dependent effects, secondary effects independent of
rf2 may  also contribute to sulforaphane, oltipraz, and oleanolic
cid’s therapeutic beneﬁts. Microarray data suggest sulforaphane-
nduced gene expression that is independent of Nrf2 in select
ell models. [32,33]. Sulforaphane was shown to inhibit inﬂam-
asomes through a Nrf2-independent mechanism, by modulation
f apoptotic pathways [34]. Oleanolic acid can induce metalloth-
onein in both mice and rats. Metallothionein has an ARE sequence
n its promoter region which is induced by Nrf1, and is shown to
rotect against acetaminophen hepatotoxicity and cadmium tox-
city [35,36]. Oltipraz is not a potent or typical Nrf2 activator and
hus its effects may  not be solely due to Nrf2 activation. Oltipraz
s known to activate aryl hydrocarbon receptor [37] and constitu-
ive androstane receptor, both of which activates NQO1 expression
38].
In summary, our results demonstrate beneﬁcial effects of Nrf2
ctivating agents on viability of human kidney cells and expres-
ion of antioxidant and efﬂux transporter genes. Agents such as
ulforaphane and oltipraz may  be potential therapies to enhance
ephro-protectant effects for patients undergoing treatment with
nown toxicants such as cisplatin. There appears to be compound
peciﬁc effects of Nrf2 activating agents on antioxidant pathways.
hile weak activation of Nrf2 was observed with Nrf2 activators,
ollectively, increased cell viability and increased mRNA expression
f Nrf2-target genes provide evidence for the beneﬁts of select Nrf2
ctivators as potential therapies. Ongoing in vitro and in vivo inves-
igations are evaluating mechanistic pathways involved in kidney
ells exposed to toxicants including cisplatin and beneﬁts of Nrf2
ctivators on nephroprotection.
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